In the breast cancer cell line MCF7, which does not originate from TNBC and was still able to respond to IFN treatment with reduced proliferation, the overexpression of IRF9, but not STAT1 or STAT2, increased the resistance of cells against the chemotherapeutic drug paclitaxel [39]. Here, IRF9 is linked to breast carcinoma.